Physician profile
Roberto Mixco
NPI 1396805255
$17,036.34
in general payments reported to CMS, 2019-2025
55 companies · $1,847 in 2025
The $1,847 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,606 · 2020: $1,398 · 2021: $1,504 · 2022: $3,741 · 2023: $2,019 · 2024: $3,921 · 2025: $1,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,511 · Travel and Lodging: $1,155 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,510.57 |
| Travel and Lodging | $1,154.58 |
| Education | $122.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $3,859.65 | 2019-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Biogen, INC. | $1,208.00 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Abbvie INC. | $955.06 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $940.18 | 2019-2025 | |
| Ucb, INC. | $901.62 | 2019-2025 | Briviact, Nayzilam |
| Emd Serono, INC. | $890.92 | 2019-2025 | Mavenclad |
| Eisai INC. | $762.82 | 2019-2025 | |
| Sk Life Science, INC. | $720.65 | 2020-2025 | |
| Lilly USA, LLC | $611.43 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Teva Pharmaceuticals USA, INC. | $511.30 | 2019-2025 | Austedo Xr, Austedo Xr |
| Celgene Corporation | $378.86 | 2020-2025 | Zeposia |
| Genzyme Corporation | $376.07 | 2019-2023 | |
| Kyowa Kirin, INC. | $322.49 | 2020-2024 | Nourianz |
| Pfizer INC. | $316.93 | 2021-2025 | |
| Tanabe Pharma America, INC. | $302.58 | 2020-2025 | Radicava |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Mixco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.